FDA

Why Contract Manufacturers Are Losing the Shield of OEM Oversight Under the New CFR/13485 Alignment Intro:The FDA’s alignment of 21 CFR Part 820 with ISO 13485:2016 doesn’t just modernize language — it reshapes accountability across the entire supply chain.For the first time, contract manufacturers and critical suppliers face expanded visibility as OEMs are now required to list, monitor, and trend supplier…

Why Suppliers Are the New Compliance Hotspot Under 13485 and CFR 820 Alignment Intro: The FDA’s planned alignment of 21 CFR Part 820 with ISO 13485:2016 is driving a renewed focus on supplier management.As regulators harmonize U.S. and international frameworks, supplier controls are becoming one of the highest-risk — and highest-priority — elements in QMS evaluations. Key Points: Closing: The…

Remote Audits Are Here to Stay — and They’re Changing the Compliance Playbook Intro: Remote audits, once a pandemic workaround, have become a recognized inspection pathway under FDA and international regulatory programs.While still supplemented by on-site visits, digital and hybrid audits are now a core element of regulatory oversight — and companies must adapt their readiness strategies…

Intro: The FDA’s new ELSA (Enhanced Lifecycle Safety and Accountability) framework signals a major shift in how regulated manufacturers will manage compliance in the years ahead.ELSA moves away from reactive inspection models toward continuous, data-driven oversight — built on digital traceability, remote review, and AI-assisted risk monitoring. Key Points: Closing: ELSA represents the next step in FDA’s vision for predictive,…